ERBB2 and non-small cell lung carcinoma: In patients with HER2 overexpressing locally advanced, recurrent, or metastatic NSCLC, T-DM1 demonstrated an ORR of 6.7–20.0%, an mPFS of 2.0–2.6 months, and an mOS of 10.9–12.2 months (Figure 1) [86,87,88].